1. Home
  2. VSEC vs DFTX Comparison

VSEC vs DFTX Comparison

Compare VSEC & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VSE Corporation

VSEC

VSE Corporation

HOLD

Current Price

$174.33

Market Cap

6.8B

ML Signal

HOLD

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$38.12

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VSEC
DFTX
Founded
1959
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
5.9B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
VSEC
DFTX
Price
$174.33
$38.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
8
Target Price
$226.29
$38.50
AVG Volume (30 Days)
289.0K
1.8M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
0.25%
N/A
EPS Growth
N/A
N/A
EPS
1.94
N/A
Revenue
$760,113,000.00
N/A
Revenue This Year
$32.16
N/A
Revenue Next Year
$21.36
N/A
P/E Ratio
$90.25
N/A
Revenue Growth
9.88
N/A
52 Week Low
$154.74
$14.62
52 Week High
$247.85
$49.70

Technical Indicators

Market Signals
Indicator
VSEC
DFTX
Relative Strength Index (RSI) 33.33 43.81
Support Level $161.74 $16.37
Resistance Level $182.62 $49.13
Average True Range (ATR) 8.49 1.88
MACD -3.33 -0.07
Stochastic Oscillator 2.23 24.89

Price Performance

Historical Comparison
VSEC
DFTX

About VSEC VSE Corporation

VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: